Asthma Clinical Trial
Official title:
MISSION Severe Asthma: Modern Innovative Solutions to Improve Outcomes in Severe Asthma. A Mixed Methods Observational Comparison of Clinical Outcomes in MISSION Versus Current Care Delivery.
MISSION is a new and novel way of delivering highly specialised asthma care and has the potential to change the way asthma care across the United Kingdom (UK) is delivered as well as services for other long term health conditions. The MISSION model is the first model of this type and the current research study aims to evaluate its success and to compare the MISSION service to current care delivery. This will be done in several different ways. The study is a mixed methods evaluation of the new service comparing outcomes before and after the intervention using retrospective data analysis and prospective qualitative interview. A control arm of patients not exposed to, but eligible for, the new intervention will also be included. The study will be conducted at Portsmouth Hospitals National Health Service (NHS) Trust and will recruit patients who attended MISSION clinics, outpatient asthma clinics, staff who attended MISSION clinics in a professional capacity and patients from GP surgeries where MISSION clinics were held who did not attend.
Purpose and design
The purpose of the study is to evaluate in detail the clinical and health economic outcomes
from the MISSION project. The MISSION clinics combined a new way of delivering asthma care
along with actively case finding patients who were not already known to specialist services
but who had uncontrolled or at risk asthma.
The aim of the study is to compare the MISSION clinic model outcomes to current clinic model
outcomes as well as performing qualitative interviews with patients who attended and staff
who took part in the project.The research study was developed by a team from Portsmouth
Hospital Trust and the University of Portsmouth including a research fellow, consultant and
Professor, research methodologist, qualitative senior lecturer and independent statistician.
A patient adviser also reviewed the lay summary and patient information sheets. The study
undergoes independent review by another clinician as part of the sponsor process.
The study is also part of an MD project for the University of Portsmouth.
Design:
This is a mixed methods study.
A quantitative analysis of data from patients who attended the MISSION Rapid Access Asthma
Clinics (RAAC), patients who attended the MISSION Severe Asthma Assessment Clinics (SAAC),
patients who were invited to the RAAC but did not attend and patients who have been referred
by their GP to the severe asthma clinic during the same time MISSION was running. The data
analysis will include asthma control, hospital admissions, GP appointments, related medical
conditions,medications, investigations and assessments done and time between appointments.
A qualitative study will be conducted using telephone interviews with patients who attended
the SAAC and health care professionals who took part in the MISSION clinics.
The aim is to recruit:
- 44 MISSION patients (of whom 20 attended both the RAAC and the SAAC),
- 132 patients who were invited to MISSION RAAC but did not attend
- 20 patients referred to the severe asthma clinic at the hospital
- 20 health care professionals who took part in the MISSION clinics
Methodology:
Participants will be approached for consent by post. They will be given time to read the
information and return the consent form to the study team. They will be given a contact
number to discuss any questions.
Once a participant has consented to the quantitative study there is no further study
procedures for the participant. Participants will be asked for consent to collect data from
their GP and hospital records for the study. This will be entered onto a form (CRF) against
a study number and then into a password protected study database held on a secure server at
Portsmouth Hospitals NHS Trust. This data will then be analysed by a statistician and
research fellow.
Participants for qualitative interview will have an interview over the telephone lasting 45
minutes to one hour. This will be recorded and transcribed. The participant will be given
the transcript to read and correct. The transcripts will then be analysed looking for
themes.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|